Jonathan S Bromberg, Suphamai Bunnapradist, Milagros Samaniego-Picota, Sanjiv Anand, Erik Stites, Philippe Gauthier, Zachary Demko, Adam Prewett, Madeleine Armer-Cabral, Kyle Marshall, Navchetan Kaur, Michelle S Bloom, Hossein Tabriziani, Sangeeta Bhorade, Matthew Cooper
BACKGROUND: Standard-of-care biomarkers for renal allograft rejection are lagging indicators, signaling existing organ injury. This precludes early intervention, when immunological cascades leading to rejection are most susceptible. Donor-derived cell-free DNA (dd-cfDNA) shows promise as an early indicator of rejection, allowing earlier and possibly more effective treatment. This analysis was designed to assess this promise using real-world dd-cfDNA testing evidence. METHODS: This retrospective analysis of the prospective, observational ProActive registry study (NCT04091984) assessed dd-cfDNA and serum creatinine levels before biopsy in 424 patients with ≥1 dd-cfDNA test (n = 1013) in the 6 mo before biopsy...
April 8, 2024: Transplantation